EA200000059A1 - Блокада cd154 как лечение синдрома ингибирования терапевтических белков - Google Patents
Блокада cd154 как лечение синдрома ингибирования терапевтических белковInfo
- Publication number
- EA200000059A1 EA200000059A1 EA200000059A EA200000059A EA200000059A1 EA 200000059 A1 EA200000059 A1 EA 200000059A1 EA 200000059 A EA200000059 A EA 200000059A EA 200000059 A EA200000059 A EA 200000059A EA 200000059 A1 EA200000059 A1 EA 200000059A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- blockade
- treatment
- syndromes
- therapeutic proteins
- inhibiting
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 208000011580 syndromic disease Diseases 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 title 1
- 230000000694 effects Effects 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 abstract 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 abstract 1
- 101150013553 CD40 gene Proteins 0.000 abstract 1
- 102000001690 Factor VIII Human genes 0.000 abstract 1
- 108010054218 Factor VIII Proteins 0.000 abstract 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 abstract 1
- 239000002981 blocking agent Substances 0.000 abstract 1
- 239000003114 blood coagulation factor Substances 0.000 abstract 1
- 229940019700 blood coagulation factors Drugs 0.000 abstract 1
- 229960000301 factor viii Drugs 0.000 abstract 1
- 230000004727 humoral immunity Effects 0.000 abstract 1
- 230000000116 mitigating effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Способы и композиции для ослабления или смягчения, подавления предотвращения, задержки появления или реверсирования синдромов ингибирования активности экзогенного белка, примером которых могут служить синдромы ингибирования активности фактора свертывания крови (например, фактора VIII). Описанные способы используют блокатор связывания CD40:CD154, такой как агент, блокирующий CD154, для ослабления или улучшения противоадаптивного биоингибирующего гуморального иммунитета, направленного на экзогенный белок, имеющий терапевтическое значение.Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5027697P | 1997-06-20 | 1997-06-20 | |
| PCT/US1998/012773 WO1998058672A1 (en) | 1997-06-20 | 1998-06-19 | Cd154 blockade therapy for therapeutic protein inhibitor syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200000059A1 true EA200000059A1 (ru) | 2000-08-28 |
| EA002512B1 EA002512B1 (ru) | 2002-06-27 |
Family
ID=21964347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200000059A EA002512B1 (ru) | 1997-06-20 | 1998-06-19 | Блокада cd154 как лечение синдрома ингибирования терапевтических белков |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20020119151A1 (ru) |
| EP (1) | EP1034001B1 (ru) |
| JP (1) | JP2002504910A (ru) |
| KR (1) | KR100567998B1 (ru) |
| CN (2) | CN1651071A (ru) |
| AT (1) | ATE272408T1 (ru) |
| AU (1) | AU733062B2 (ru) |
| BG (1) | BG64436B1 (ru) |
| BR (1) | BR9810755A (ru) |
| CA (1) | CA2294138A1 (ru) |
| CZ (1) | CZ295805B6 (ru) |
| DE (1) | DE69825473T2 (ru) |
| EA (1) | EA002512B1 (ru) |
| EE (1) | EE9900587A (ru) |
| ES (1) | ES2226152T3 (ru) |
| HK (1) | HK1031825A1 (ru) |
| HU (1) | HUP0002048A3 (ru) |
| IL (1) | IL133305A0 (ru) |
| IS (1) | IS2097B (ru) |
| NO (1) | NO996274L (ru) |
| NZ (1) | NZ502051A (ru) |
| PT (1) | PT1034001E (ru) |
| SK (1) | SK285962B6 (ru) |
| TR (1) | TR199903141T2 (ru) |
| WO (1) | WO1998058672A1 (ru) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2343916A1 (en) * | 1998-09-21 | 2000-03-30 | Genetics Institute, Inc. | Methods of downmodulating the immune response to therapeutic proteins |
| AU2001251612A1 (en) | 2000-04-14 | 2001-10-30 | Millennium Pharmaceuticals, Inc. | Roles of jak/stat family members in tolerance induction |
| CN1441675A (zh) | 2000-05-12 | 2003-09-10 | 贝斯以色列护理医疗中心有限公司 | 免疫抑制组合物及方法 |
| IES20030305A2 (en) * | 2002-04-23 | 2003-10-29 | Desmond Joseph Fitzgerald | Inhibition of platelet aggregation |
| DE602004029252D1 (de) * | 2003-06-13 | 2010-11-04 | Biogen Idec Inc | Aglycosyl-anti-cd154 (cd40-ligand) antikörper und deren verwendungen |
| ES2353222T3 (es) * | 2003-06-13 | 2011-02-28 | Biogen Idec Ma Inc. | Anticuerpos anti-cd154 (ligando cd40) aglicosilados y usos de los mismos. |
| AU2011224032B2 (en) * | 2003-06-13 | 2013-01-31 | Biogen Ma Inc. | Aglycosyl Anti-CD154 (CD40 Ligand) Antibodies and Uses Thereof |
| ATE473016T1 (de) | 2003-11-04 | 2010-07-15 | Novartis Vaccines & Diagnostic | Verfahren zur behandlung von krebs mit expression des cd40-antigens |
| GEP20105059B (en) | 2004-07-26 | 2010-08-10 | Biogen Idec Inc | Anti-cd154 antibodies |
| WO2006017574A1 (en) * | 2004-08-03 | 2006-02-16 | Mayo Foundation For Medical Education And Research | Improving treatments |
| ES2429564T3 (es) | 2005-05-18 | 2013-11-15 | Novartis Ag | Procedimientos para el diagnóstico y tratamiento de enfermedades que tienen un componente autoinmune y/o inflamatorio |
| MX2008013508A (es) | 2006-04-21 | 2008-10-31 | Novartis Ag | Composiciones farmaceuticas de anticuerpos antagonistas anti-cd40. |
| US9382327B2 (en) | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| US9447156B2 (en) | 2011-05-17 | 2016-09-20 | St. Jude Children's Research Hospital | Methods and compositions for inhibiting neddylation of proteins |
| US20140004131A1 (en) | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474771A (en) * | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| ZA946765B (en) * | 1993-09-02 | 1996-02-15 | Dartmouth College | Methods of prolonged suppression of humoral immunity |
| US5872154A (en) * | 1995-02-24 | 1999-02-16 | The Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant adenovirus |
| DE69837322T2 (de) * | 1997-01-10 | 2007-11-22 | Biogen Idec Ma Inc., Cambridge | Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln |
-
1998
- 1998-06-19 EP EP98931391A patent/EP1034001B1/en not_active Expired - Lifetime
- 1998-06-19 NZ NZ502051A patent/NZ502051A/en unknown
- 1998-06-19 PT PT98931391T patent/PT1034001E/pt unknown
- 1998-06-19 WO PCT/US1998/012773 patent/WO1998058672A1/en active IP Right Grant
- 1998-06-19 TR TR1999/03141T patent/TR199903141T2/xx unknown
- 1998-06-19 HU HU0002048A patent/HUP0002048A3/hu unknown
- 1998-06-19 AT AT98931391T patent/ATE272408T1/de not_active IP Right Cessation
- 1998-06-19 JP JP50339199A patent/JP2002504910A/ja not_active Ceased
- 1998-06-19 ES ES98931391T patent/ES2226152T3/es not_active Expired - Lifetime
- 1998-06-19 EA EA200000059A patent/EA002512B1/ru not_active IP Right Cessation
- 1998-06-19 CN CNA2004100978650A patent/CN1651071A/zh active Pending
- 1998-06-19 EE EEP199900587A patent/EE9900587A/xx unknown
- 1998-06-19 SK SK1803-99A patent/SK285962B6/sk unknown
- 1998-06-19 CN CN98806403A patent/CN1261285A/zh active Pending
- 1998-06-19 IL IL13330598A patent/IL133305A0/xx unknown
- 1998-06-19 DE DE69825473T patent/DE69825473T2/de not_active Expired - Fee Related
- 1998-06-19 CA CA002294138A patent/CA2294138A1/en not_active Abandoned
- 1998-06-19 BR BR9810755-0A patent/BR9810755A/pt not_active Application Discontinuation
- 1998-06-19 AU AU81536/98A patent/AU733062B2/en not_active Ceased
- 1998-06-19 KR KR1019997011990A patent/KR100567998B1/ko not_active IP Right Cessation
- 1998-06-19 CZ CZ19994588A patent/CZ295805B6/cs not_active IP Right Cessation
-
1999
- 1999-11-26 IS IS5274A patent/IS2097B/is unknown
- 1999-12-17 NO NO996274A patent/NO996274L/no not_active Application Discontinuation
-
2000
- 2000-01-18 BG BG104092A patent/BG64436B1/bg unknown
-
2001
- 2001-02-14 HK HK01101074A patent/HK1031825A1/xx not_active IP Right Cessation
-
2002
- 2002-04-19 US US10/127,228 patent/US20020119151A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200000059A1 (ru) | Блокада cd154 как лечение синдрома ингибирования терапевтических белков | |
| NO953093D0 (no) | Forbindelser med både sterk kalsiumantagonist- og antioksidantvirkning, samt anvendelse derav som cellebeskyttende midler | |
| ID21526A (id) | 4-hidroksiquinolin-3-karboksamida dan hidrazida sebagai bahan anti-virus | |
| IL157041A0 (en) | Monoclonal antibodies to the clfa protein and method of use in treating and preventing infections | |
| ID27787A (id) | Senyawa, komposisi dan metode untuk pengobatan atau pencegahan infeksi yang disebabkan oleh virus dan penyakit-penyakit yang berkaitan | |
| MXPA02012443A (es) | Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos. | |
| HK1069316A1 (en) | Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases | |
| DE69713388D1 (de) | Verwendung von niedermolekularen aminoalkoholen in ophthalmologischen präparaten | |
| AU2002360592A8 (en) | Inhibitors of hepatitis c virus | |
| EA200300849A1 (ru) | Способы лечения или профилактики кожных заболеваний с помощью cd2-связывающих агентов | |
| ATE290548T1 (de) | Expressionsblockierung von virulenten faktoren in s. aureus | |
| ES2160643T3 (es) | Composiciones que contienen g-csf y proteina de union al tnf. | |
| EP1155677A3 (en) | Methods and compositions for inhibiting free radical polymerization in skin and hair | |
| AU2001290962A1 (en) | Methods of preparing immune globulin and uses thereof | |
| HK1045456B (zh) | 病毒炎性調節蛋白在阻斷異種移植排斥中的治療新用途 | |
| WO2000064468A3 (en) | Therapeutic compositions and methods for enhancing angiogenesis | |
| NO984189L (no) | FremgangsmÕte for behandling av bipolar forstyrrelse | |
| ATE255594T1 (de) | Hepatitis b inhibitoren | |
| NO20000007D0 (no) | Anvendelse av veksthormon i sammensetninger til behandling av insulinresistens i hjertet samt for å oeke proteinkinase-B(PKB)- aktivitet | |
| UA94022C2 (ru) | Применение ингибитора il-18 для лечения и/или предупреждения алкогольного гепатита | |
| GB2233559A (en) | Antibodies for use in antilymphocyte antibody therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |